NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 46 filers reported holding NABRIVA THERAPEUTICS PLC in Q3 2018. The put-call ratio across all filers is 3.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $33,000 | -21.4% | 62,669 | 0.0% | 0.00% | – |
| Q2 2020 | $42,000 | +16.7% | 62,669 | 0.0% | 0.00% | – |
| Q1 2020 | $36,000 | -78.0% | 62,669 | -50.0% | 0.00% | – |
| Q4 2019 | $164,000 | +31.2% | 125,338 | +100.0% | 0.00% | – |
| Q3 2019 | $125,000 | -17.8% | 62,669 | 0.0% | 0.00% | – |
| Q2 2019 | $152,000 | +33.3% | 62,669 | +34.1% | 0.00% | – |
| Q1 2019 | $114,000 | -16.2% | 46,739 | -50.0% | 0.00% | – |
| Q4 2018 | $136,000 | +7.9% | 93,478 | +100.0% | 0.00% | – |
| Q3 2018 | $126,000 | -22.2% | 46,739 | 0.0% | 0.00% | – |
| Q2 2018 | $162,000 | +170.0% | 46,739 | +286.6% | 0.00% | – |
| Q1 2018 | $60,000 | -16.7% | 12,089 | 0.0% | 0.00% | – |
| Q4 2017 | $72,000 | -27.3% | 12,089 | 0.0% | 0.00% | – |
| Q3 2017 | $99,000 | – | 12,089 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,074,190 | $33,368,000 | 6.74% |
| Novo Holdings A/S | 2,903,800 | $23,782,000 | 3.10% |
| PURA VIDA INVESTMENTS, LLC | 425,000 | $3,481,000 | 1.02% |
| ACUTA CAPITAL PARTNERS, LLC | 400,000 | $3,276,000 | 0.59% |
| Monashee Investment Management LLC | 188,000 | $1,540,000 | 0.58% |
| Orbimed Advisors | 3,919,600 | $32,102,000 | 0.31% |
| FT Options LLC | 20,000 | $164,000 | 0.25% |
| Rock Springs Capital Management LP | 625,000 | $5,119,000 | 0.24% |
| Rubric Capital Management LP | 300,000 | $2,457,000 | 0.22% |
| Ghost Tree Capital, LLC | 120,000 | $983,000 | 0.21% |